Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -
Please visit our MS learning channel on YouTube, which provides hundreds of MS videos presented by MS Experts across the USA, from many of our recorded education programs. Archived here: www.youtube.com/msviewsandnews -- Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram
Important Resources for the MS community are found on the left side of this blog.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Saturday, October 2, 2010
AMPYRA® - a medication indicated as a treatment to improve walking in people with multiple sclerosis (MS)
Thursday, September 30, 2010
Other potential serious risks are described. The long-term safety of Gilenya is unknown at this time. Other phase III clinical trials of Gilenya, including one involving people with primary progressive MS, are still underway, as are extension studies involving those who have completed trials. These and other post-marketing studies should provide additional data on the safety and efficacy of Gilenya.
Wednesday, September 29, 2010
Tuesday, September 28, 2010
Patients with multiple sclerosis who smoke appear to experience a more rapid progression of their disease
Cigarette smokers are at higher risk of developing multiple sclerosis (MS), according to background information in the article. However, the effect of smoking on the progression of MS remains uncertain.
Brian C. Healy, Ph.D., of Brigham and Women's Hospital, Harvard Medical School and Massachusetts General Hospital, Boston, and colleagues studied 1,465 patients with MS who visited a referral center between February 2006 and August 2007. Participants had an average age of 42 and had MS for an average of 9.4 years. Their progression was assessed by clinical characteristics as well as by magnetic resonance imaging (MRI) over an average of 3.29 years.
Monday, September 27, 2010
Continue reading this information and leave your comments either on facebook or below this blog entry
UPDATE: There have been some changes in the recommendations for FluMist and people with multiple sclerosis (MS) in 2010. Looks like MS is no longer a contraindication for getting vaccinated with FluMist, although I have had a hard time finding specific current information about people on certain drugs, like Tysabri, Solu-Medrol and the chemo-based therapies. I write about my findings in my recent blog, FluMist and Multiple Sclerosis Update and True Confession.
Read More, Click here